1932

Abstract

Cystic fibrosis (CF) is an inherited multisystemic disease that can cause progressive bronchiectasis, pancreatic endocrine and exocrine insufficiency, distal intestinal obstruction syndrome, liver dysfunction, and other disorders. Traditional therapies focused on the treatment or prevention of damage to each organ system with incremental modalities such as nebulized medications for the lungs, insulin for diabetes, and supplementation with pancreatic enzymes. However, the advent of highly effective modulator therapies that target specific cystic fibrosis transmembrane conductance regulator protein malformations resulting from individual genetic mutations has transformed the lives and prognosis for persons with CF.

[Erratum, Closure]

An erratum has been published for this article:
Erratum: Cystic Fibrosis Modulator Therapies
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042921-021447
2023-01-27
2024-04-22
Loading full text...

Full text loading...

/deliver/fulltext/med/74/1/annurev-med-042921-021447.html?itemId=/content/journals/10.1146/annurev-med-042921-021447&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Riordan JR, Rommens JM, Kerem B et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–73
    [Google Scholar]
  2. 2.
    Rommens JM, Iannuzzi MC, Kerem B et al. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059–65
    [Google Scholar]
  3. 3.
    Kerem B, Rommens JM, Buchanan JA et al. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073–80
    [Google Scholar]
  4. 4.
    Davis PB. 2006. Cystic fibrosis since 1938. Am. J. Respir. Crit. Care Med. 173:475–82
    [Google Scholar]
  5. 5.
    Elborn JS. 2016. Cystic fibrosis. Lancet 388:2519–31
    [Google Scholar]
  6. 6.
    O'Sullivan BP, Freedman SD 2009. Cystic fibrosis. Lancet 373:1891–904
    [Google Scholar]
  7. 7.
    Kelly J. 2017. Environmental scan of cystic fibrosis research worldwide. J. Cystic Fibrosis 16:367–70
    [Google Scholar]
  8. 8.
    Cystic Fibrosis Foundation 2021. 2020 Patient registry annual data report Rep., Cystic Fibrosis Found. Bethesda, MD: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf
  9. 9.
    Orenti A, Zolin A, Jung A et al. 2021. 2019 ECFS Patient Registry annual data report Rep., Eur. Cystic Fibrosis Soc. Karup, Denmark: https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report_2019_v1_16Feb2022.pdf
  10. 10.
    Guo X, Liu K, Liu Y et al. 2018. Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases. Orphanet. J. Rare. Dis. 13:224
    [Google Scholar]
  11. 11.
    Stewart C, Pepper MS. 2016. Cystic fibrosis on the African continent. Genet. Med. 18:653–62
    [Google Scholar]
  12. 12.
    Yamashiro Y, Shimizu T, Oguchi S et al. 1997. The estimated incidence of cystic fibrosis in Japan. J. Pediatr. Gastroenterol. Nutr. 24:544–47
    [Google Scholar]
  13. 13.
    Strom CM, Crossley B, Buller-Buerkle A et al. 2011. Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis. Genet. Med. 13:166–72
    [Google Scholar]
  14. 14.
    Schrijver I, Pique L, Graham S et al. 2016. The spectrum of CFTR variants in nonwhite cystic fibrosis patients: implications for molecular diagnostic testing. J. Mol. Diagn. 18:39–50
    [Google Scholar]
  15. 15.
    McGarry ME, McColley SA. 2021. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr. Pulmonol. 56:1496–503
    [Google Scholar]
  16. 16.
    CFTR2. 2022 Clinical and Functional Translation of CFTR https://www.cftr2.org/. Accessed Feb. 28, updated Apr. 29, 2022
  17. 17.
    Anderson MP, Gregory RJ, Thompson S et al. 1991. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253:202–5
    [Google Scholar]
  18. 18.
    Liu F, Zhang Z, Csanady L et al. 2017. Molecular structure of the human CFTR ion channel. Cell 169:85–95.e8
    [Google Scholar]
  19. 19.
    Rowe SM, Miller S, Sorscher EJ. 2005. Cystic fibrosis. N. Engl. J. Med. 352:1992–2001
    [Google Scholar]
  20. 20.
    Sosnay PR, Siklosi KR, Van Goor F et al. 2013. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat. Genet. 45:1160–67
    [Google Scholar]
  21. 21.
    Veit G, Avramescu RG, Chiang AN et al. 2016. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol. Biol. Cell 27:424–33
    [Google Scholar]
  22. 22.
    Clancy JP, Rowe SM, Accurso FJ et al. 2012. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67:12–18
    [Google Scholar]
  23. 23.
    Wainwright CE, Elborn JS, Ramsey BW et al. 2015. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med. 373:220–31
    [Google Scholar]
  24. 24.
    Haq I, Almulhem M, Soars S et al. 2022. Precision medicine based on CFTR genotype for people with cystic fibrosis. Pharmacogenom. Personalized Med. 15:91–104
    [Google Scholar]
  25. 25.
    Kalydeco (ivacaftor) [package insert]. Cambridge, MA: Vertex Pharmaceuticals Inc.; 2012.
  26. 26.
    ORKAMBI (lumacaftor/ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Inc.; 2015.
  27. 27.
    SYMDEKO (tezacaftor/ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Inc.; 2018.
  28. 28.
    TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) [package insert] Boston, MA: Vertex Pharmaceuticals Inc.; 2019.
  29. 29.
    Castellani C, Duff AJA, Bell SC et al. 2018. ECFS best practice guidelines: the 2018 revision. J. Cystic Fibrosis 17:153–78
    [Google Scholar]
  30. 30.
    Shteinberg M, Haq IJ, Polineni D, Davies JC. 2021. Cystic fibrosis. Lancet 397:2195–211
    [Google Scholar]
  31. 31.
    Yu H, Burton B, Huang CJ et al. 2012. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cystic Fibrosis 11:237–45
    [Google Scholar]
  32. 32.
    Liu F, Zhang Z, Levit A et al. 2019. Structural identification of a hotspot on CFTR for potentiation. Science 364:1184–88
    [Google Scholar]
  33. 33.
    Yeh HI, Qiu L, Sohma Y, Conrath K et al. 2019. Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770. J. Gen. Physiol. 151:912–28
    [Google Scholar]
  34. 34.
    Cui G, Stauffer BB, Imhoff BR et al. 2019. VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level. Sci. Rep. 9:13460
    [Google Scholar]
  35. 35.
    Van Goor F, Hadida S, Grootenhuis PD et al. 2009. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. PNAS 106:18825–30
    [Google Scholar]
  36. 36.
    Accurso FJ, Rowe SM, Clancy JP et al. 2010. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363:1991–2003
    [Google Scholar]
  37. 37.
    Ramsey BW, Davies J, McElvaney NG et al. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365:1663–72
    [Google Scholar]
  38. 38.
    Flume PA, Liou TG, Borowitz DS et al. 2012. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142:718–24
    [Google Scholar]
  39. 39.
    Dalemans W, Barbry P, Champigny G et al. 1991. Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature 354:526–28
    [Google Scholar]
  40. 40.
    Quittner AL, Buu A, Messer MA et al. 2005. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128:2347–54
    [Google Scholar]
  41. 41.
    Moss RB, Flume PA, Elborn JS et al. 2015. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir. Med. 3:524–33
    [Google Scholar]
  42. 42.
    De Boeck K, Munck A, Walker S et al. 2014. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J. Cystic Fibrosis 13:674–80
    [Google Scholar]
  43. 43.
    Davies JC, Cunningham S, Harris WT et al. 2016. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir. Med. 4:107–15
    [Google Scholar]
  44. 44.
    Rowe SM, Daines C, Ringshausen FC et al. 2017. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N. Engl. J. Med. 377:2024–35
    [Google Scholar]
  45. 45.
    Van Goor F, Yu H, Burton B, Hoffman BJ. 2014. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cystic Fibrosis 13:29–36
    [Google Scholar]
  46. 46.
    Cystic Fibrosis Found 2019. 2018 Patient Registry annual data report Rep., Cystic Fibrosis Found. Bethesda, MD:
  47. 47.
    Bobadilla JL, Macek M Jr., Fine JP, Farrell PM. 2002. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening. Hum. Mutat. 19:575–606
    [Google Scholar]
  48. 48.
    Van Goor F, Hadida S, Grootenhuis PD et al. 2011. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. PNAS 108:18843–48
    [Google Scholar]
  49. 49.
    Loo TW, Bartlett MC, Clarke DM. 2013. Corrector VX-809 stabilizes the first transmembrane domain of CFTR. Biochem. Pharmacol. 86:612–19
    [Google Scholar]
  50. 50.
    Boyle MP, Bell SC, Konstan MW et al. 2014. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir. Med. 2:527–38
    [Google Scholar]
  51. 51.
    Elborn JS, Ramsey BW, Boyle MP et al. 2016. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir. Med. 4:617–26
    [Google Scholar]
  52. 52.
    Rowe SM, McColley SA, Rietschel E et al. 2017. Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR. Ann. Am. Thoracic Soc. 14:213–19
    [Google Scholar]
  53. 53.
    Donaldson SH, Pilewski JM, Griese M et al. 2018. Tezacaftor/ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am. J. Respir. Crit. Care Med. 197:214–24
    [Google Scholar]
  54. 54.
    Hubert D, Chiron R, Camara B et al. 2017. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J. Cystic Fibrosis 16:388–91
    [Google Scholar]
  55. 55.
    Taylor-Cousar JL, Munck A, McKone EF et al. 2017. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N. Engl. J. Med. 377:2013–23
    [Google Scholar]
  56. 56.
    Taylor-Cousar JL, Mall MA, Ramsey BW et al. 2019. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res. 5:00082–2019
    [Google Scholar]
  57. 57.
    Keating D, Marigowda G, Burr L et al. 2018. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379:1612–20
    [Google Scholar]
  58. 58.
    Davies JC, Moskowitz SM, Brown C et al. 2018. VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379:1599–611
    [Google Scholar]
  59. 59.
    Middleton PG, Mall MA, Drevinek P et al. 2019. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381:1809–19
    [Google Scholar]
  60. 60.
    Heijerman HGM, McKone EF, Downey DG et al. 2019. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394:1940–48
    [Google Scholar]
  61. 61.
    Zemanick ET, Taylor-Cousar JL, Davies J et al. 2021. A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am. J. Respir. Crit. Care Med. 203:1522–32
    [Google Scholar]
  62. 62.
    McKone EF, Borowitz D, Drevinek P et al. 2014. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir. Med. 2:902–10
    [Google Scholar]
  63. 63.
    Pilewski JM, De Boeck K, Nick JA et al. 2020. Long-term ivacaftor in people aged 6 years and older with cystic fibrosis with ivacaftor-responsive mutations. Pulm. Ther. 6:303–13
    [Google Scholar]
  64. 64.
    Volkova N, Moy K, Evans J et al. 2020. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J. Cystic Fibrosis 19:68–79
    [Google Scholar]
  65. 65.
    Nichols AL, Davies JC, Jones D, Carr SB. 2020. Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. Paediatr. Respir. Rev. 35:99–102
    [Google Scholar]
  66. 66.
    Konstan MW, McKone EF, Moss RB et al. 2017. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir. Med. 5:107–18
    [Google Scholar]
  67. 67.
    Muilwijk D, Bierlaagh M, van Mourik P et al. 2021. Prediction of real-world long-term outcomes of people with CF homozygous for the F508del mutation treated with CFTR modulators. J. Personalized Med. 11:1376
    [Google Scholar]
  68. 68.
    Flume PA, Biner RF, Downey DG et al. 2021. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir. Med. 9:733–46
    [Google Scholar]
  69. 69.
    Griese M, Costa S, Linnemann RW et al. 2021. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial. Am. J. Respir. Crit. Care Med. 203:381–85
    [Google Scholar]
  70. 70.
    Barry PJ, Taylor-Cousar JL. 2021. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world—opportunities and challenges. Curr. Opin. Pulm. Med. 27:554–66
    [Google Scholar]
  71. 71.
    Scully KJ, Marchetti P, Sawicki GS et al. 2021. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J. Cystic Fibrosis 21:258–63
    [Google Scholar]
  72. 72.
    Taylor-Cousar JL, Jain R 2021. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J. Cystic Fibrosis 20:402–6
    [Google Scholar]
  73. 73.
    Nichols DP, Paynter AC, Heltshe SL et al. 2021. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial. Am. J. Respir. Crit. Care Med. 205:529–39
    [Google Scholar]
  74. 74.
    Beswick DM, Humphries SM, Balkissoon CD et al. 2022. Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes. Ann. Am. Thoracic Soc. 19:12–19
    [Google Scholar]
  75. 75.
    Bessonova L, Volkova N, Higgins M et al. 2018. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax 73:731–40
    [Google Scholar]
  76. 76.
    Maisonneuve P, Lowenfels AB. 2022. Cancer in cystic fibrosis: a narrative review of prevalence, risk factors, screening, and treatment challenges: adult cystic fibrosis series. Chest 161:356–64
    [Google Scholar]
  77. 77.
    Thornton C, Somayaji R, Chu A, Parkins MD 2022. Human papillomavirus (HPV) and cervical dysplasia in adult female cystic fibrosis (CF) lung transplant recipients. Thorax 77:625–27
    [Google Scholar]
  78. 78.
    Poore TS, Taylor-Cousar JL, Zemanick ET. 2022. Cardiovascular complications in cystic fibrosis: a review of the literature. J. Cystic Fibrosis 21:18–25
    [Google Scholar]
  79. 79.
    Andersen HU, Lanng S, Pressler T et al. 2006. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 29:2660–63
    [Google Scholar]
  80. 80.
    Perrin FM, Serino W. 2010. Ischaemic heart disease—a new issue in cystic fibrosis?. J. R. Soc. Med. 103:Suppl. 1S44–48
    [Google Scholar]
  81. 81.
    Kazmerski TM, Jain R, Lee M, Taylor-Cousar JL. 2022. Parenthood impacts short-term health outcomes in people with cystic fibrosis. J. Cystic Fibrosis 21:662–68
    [Google Scholar]
  82. 82.
    McGarry ME, Williams WA 2nd, McColley SA 2019. The demographics of adverse outcomes in cystic fibrosis. Pediatr. Pulmonol. 54:Suppl. 3S74–83
    [Google Scholar]
  83. 83.
    Cystic Fibrosis Found 2022. Drug development pipeline. Cystic Fibrosis Foundation https://apps.cff.org/trials/pipeline/
    [Google Scholar]
  84. 84.
    Fajac I, Sermet-Gaudelus I. 2021. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators. Curr. Opin. Pulm. Med. 27:567–74
    [Google Scholar]
/content/journals/10.1146/annurev-med-042921-021447
Loading
/content/journals/10.1146/annurev-med-042921-021447
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error